Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Kitov Pharma Ltd (KTOV)

Kitov Pharma Ltd (KTOV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Purple Biotech to Present at the B. Riley Oncology Investor Conference Globe NewsWire - Mon Jan 18, 2021

REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune...

PPBT : 6.98 (-1.69%)
KTOV : 4.17 (+2.21%)
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell Globe NewsWire - Mon Jan 4, 2021

Virtual Bell-Ringing Ceremony in Celebration of Company’s Recent Name Change to Purple Biotech

PPBT : 6.98 (-1.69%)
KTOV : 4.17 (+2.21%)
Kitov Announces Name Change to Purple Biotech Ltd. Globe NewsWire - Thu Dec 10, 2020

New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies

KTOV : 4.17 (+2.21%)
Kitov Pharma to Participate in November Investor Conferences Globe NewsWire - Wed Nov 11, 2020

TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...

KTOV : 4.17 (+2.21%)
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb Globe NewsWire - Mon Nov 9, 2020

The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer

KTOV : 4.17 (+2.21%)
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219 Globe NewsWire - Tue Oct 27, 2020

Patent covers NT219’s combinations with multiple 2 nd and 3 rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)

KTOV : 4.17 (+2.21%)
New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference Globe NewsWire - Fri Oct 16, 2020

Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance

KTOV : 4.17 (+2.21%)

Barchart Exclusives

How Surging AI Demand Could Drive This Dividend Stock Higher Barchart - 54 minutes ago
Eaton, a diversified power management company, is poised to benefit from the surging demand for AI-driven data centers, with its innovative power solutions and strong dividend growth making it an attractive investment opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot